Infective Endocarditis, a Current Perspective: Clinical and Epidemiological Profile in a High-Volume Chilean Tertiary Centre Between 2021–2023
Pathogens · 10.07.2026 · 15 (7) · 727
DOI: 10.3390/pathogens15070727 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Pathogens, online erschienen am 10.07.2026. Verfasst von Ignacio Hernan Pineda Etcheber und 4 weiteren Autor:innen. Beteiligte Einrichtung: Internal Medicine Department, Universidad de La Frontera, Temuco 4781218, Chile. Hauptthemen laut MEDLINE: Endocarditis, Endocarditis, Bacterial. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Infective endocarditis (IE) is a severe pathology with recent changes in its epidemiological profile, characterised by older patients with more comorbidities. The objective of this study is to describe the clinical and microbiological characteristics, as well as potential factors associated with mortality, of patients with IE in a tertiary academic centre. Material and Methods: Descriptive, retrospective, and observational study of patients over 18 years of age with a confirmed diagnosis of IE, conducted between 2021 and 2023 at the Dr Hernán Henríquez Aravena Hospital in Temuco, Chile. Biodemographic variables, risk factors, microbiology, echocardiographic findings, and complications were analysed using descriptive statistics and logistic regression models.
Results
119 patients were included (average age 60 years; 65.5% male; 28.5% rural). The most frequent risk factors were arterial hypertension (55%) and diabetes mellitus (29%). 18% were on haemodialysis (HD). Microbiological isolation was achieved in 78.1% of cases, with Streptococcus gallolyticus the most frequent isolate (16.8%), followed by Staphylococcus aureus (15.1%) and coagulase-negative Staphylococcus (15.1%). Complications were present in 69% of cases, mainly emboli (43%) and septic shock (23%)—59.6% required surgery. Global mortality was 44.5%, with a decreasing annual trend (from 58% in 2021 to 33% in 2023). Comorbidities and complications independently associated with mortality were chronic renal failure on HD (OR 5.76; p = 0.001), heart failure (OR 3.13; p = 0.025), and septic shock (OR 3.31; p = 0.016).
Conclusions
IE in this centre presents an aggressive profile and a high burden of comorbidities. The prevalence of S. gallolyticus is a notable regional observation not reported in similar populations. Mortality remains high, with an improving trend.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Internal Medicine Department, Universidad de La Frontera, Temuco 4781218, Chile.
- Intensive Care Unit, Complejo Asistencial de Padre Las Casas, Padre Las Casas 4850000, Chile.
- Cardiovascular Centre, "Dr. Hernán Henríquez Aravena" Hospital, Temuco 4781151, Chile.
- Medicine School, Universidad de La Frontera, Temuco 4781218, Chile.
ORCID-Profile: Mauricio Soto Vasquez
Zitieren
APA
Pineda Etcheber, I. H., Mutel Gonzalez, C., Bascuñan Maiz, J. A., Cesped Astete, A., & Soto Vasquez, M. (2026). Infective Endocarditis, a Current Perspective: Clinical and Epidemiological Profile in a High-Volume Chilean Tertiary Centre Between 2021–2023. Pathogens, 15(7), 727. https://doi.org/10.3390/pathogens15070727
Vancouver
Pineda Etcheber IH, Mutel Gonzalez C, Bascuñan Maiz JA, Cesped Astete A, Soto Vasquez M. Infective Endocarditis, a Current Perspective: Clinical and Epidemiological Profile in a High-Volume Chilean Tertiary Centre Between 2021–2023. Pathogens. 2026;15(7):727. doi:10.3390/pathogens15070727
BibTeX
@article{PinedaEtcheber2026,
author = {Pineda Etcheber, Ignacio Hernan and Mutel Gonzalez, Cheryld and Bascuñan Maiz, Javiera Antonia and Cesped Astete, Antonia and Soto Vasquez, Mauricio},
title = {Infective Endocarditis, a Current Perspective: Clinical and Epidemiological Profile in a High-Volume Chilean Tertiary Centre Between 2021–2023},
journal = {Pathogens},
year = {2026},
volume = {15},
number = {7},
pages = {727},
doi = {10.3390/pathogens15070727}
}
EUVIMED